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Abstract
Serine proteases serve many functions in normal biological processes. These functions are often usurped by cancer cells to
allow progression of tumors by increasing the growth and metastatic potential of the neoplasia. Here, we have used a
polymerase chain reaction (PCR)-based strategy to clone Tumor Associated Differentially-expressed Gene-12 (TADG-12), a
new serine protease from ovarian carcinoma. This technique also revealed a variant splicing form of TADG-12 that could
lead to a truncated protein product. Semi-quantitative PCR showed that TADG-12 is overexpressed in 41 of 55 ovarian
cancer specimens relative to normal expression, and the variant form, TADG-12V is found at increased levels in 8 of
22 carcinomas examined. Northern blot revealed three transcripts, the largest of which is approximately 2.4 kb. An ovarian
tumor cDNA library was screened, and the entire cDNA of TADG-12 has been identified. This sequence encodes a putative
protein of 454 amino acids which includes a potential transmembrane domain, an LDL receptor-like domain, a scavenger
receptor cysteine-rich domain, and a serine protease domain. These features imply that TADG-12 will be at the cell surface,
and it may be useful as a molecular target for therapy or a diagnostic marker. ß 2000 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Tumor cells rely on the expression of a concert of
proteases to be released from their primary site and
move to distant sites to in£ict lethality. This meta-
static nature is the result of an aberrant expression
pattern of proteases by tumor cells and also by stro-
mal cells surrounding the tumors [1^3]. For most
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tumors to become metastatic, they must degrade
their surrounding extracellular matrix components,
degrade basement membranes to gain access to the
bloodstream or lymph system, and repeat this pro-
cess in reverse fashion to settle in a secondary host
site [3^6]. All of these processes rely upon what now
appears to be a synchronized protease cascade. In
addition, tumor cells use the power of proteases to
activate growth and angiogenic factors that allow the
tumor to grow progressively [1]. Therefore, much
research has been aimed at the identi¢cation of tu-
mor-associated proteases and the inhibition of these
enzymes for therapeutic means. More importantly,
the secreted nature and/or high level expression of
many of these proteases allows for their detection
at aberrant levels in patient serum, e.g., the pros-
tate-speci¢c antigen (PSA), which allows for early
diagnosis of prostate cancer [7].
For many forms of cancer, diagnosis and treat-
ment has improved dramatically in the last 10 years.
However, the 5-year survival rate for ovarian cancer
remains below 50% due in large part to the vague
symptoms which allow for progression of the disease
to an advanced stage prior to diagnosis [8]. Although
the exploitation of the CA125 antigen has been use-
ful as a marker for monitoring recurrence of ovarian
cancer, it has not proven to be an ideal marker for
early diagnosis. Therefore, new markers that may be
secreted or released from cells and which are highly
expressed by ovarian tumors could provide a useful
tool for the early diagnosis and for therapeutic inter-
vention in patients with ovarian carcinoma.
To examine the serine proteases expressed by ovar-
ian cancers, we used a polymerase chain reaction
(PCR)-based di¡erential display technique utilizing
redundant PCR primers designed to the most highly
conserved amino acids in these proteins [9]. In pre-
vious studies using this technique, we have identi¢ed
several proteases as being signi¢cantly overexpressed
in ovarian carcinoma including the stratum corneum
chymotryptic enzyme (SCCE), hepsin, TADG-14,
protease M, TADG-15, and by a similar strategy,
the metalloproteinase, MMP-7 [9^14]. Here we de-
scribe a novel cell-surface, multi-domain serine pro-
tease, named Tumor Associated Di¡erentially-ex-
pressed Gene-12 (TADG-12), that appears to be
overexpressed in many ovarian tumors. The extracel-
lular nature of TADG-12 may render tumors suscep-
tible to detection via a TADG-12 speci¢c assay. In
addition, a splicing variant of TADG-12, named
TADG-12V, was detected at elevated levels in 35%
of the tumors examined. TADG-12V encodes a trun-
cated form of TADG-12 with an altered amino acid
sequence that may be a unique tumor speci¢c target
for future therapeutic approaches.
2. Materials and methods
2.1. mRNA extraction and cDNA synthesis
Sixty-nine ovarian tumors (four benign tumors,
ten low malignant potential tumors and 55 carcino-
mas) and ten normal ovaries were obtained from
surgical specimens and frozen in liquid nitrogen. Tu-
mors were examined by independent pathologists
and diagnosed according to the International Feder-
ation of Gynecologic Oncology guidelines [15]. Se-
rous, mucinous, endometrioid, and clear cell tumors
are the most common epithelial cancers of the ovary.
Serous carcinoma represents approximately 80% of
all cases diagnosed, mucinous tumors account for
approximately 10% of total cases, and a clear cell
and endometrioid represent approximately 5% each.
Low malignant potential (LMP) tumors are border-
line malignant disease that show no invasion through
the basement membrane upon microscopic examina-
tion. The human ovarian carcinoma cell lines SW
626 and Caov 3, the human breast carcinoma cell
lines MDA-MB-231 and MDA-MB-435S were pur-
chased from the American Type Culture Collection
(Rockville, MD). Cells were cultured to sub-con£u-
ency in Dulbecco’s modi¢ed Eagle’s medium, supple-
mented with 10% (v/v) fetal bovine serum and anti-
biotics.
Extraction of mRNA and cDNA synthesis were
carried out by the methods described previously
[14^17]. mRNA was isolated by using a RiboSep
mRNA isolation kit (Becton Dickinson Labware).
In this procedure, poly(A)+mRNA was isolated di-
rectly from the tissue lysate using the a⁄nity chro-
matography media oligo(dT) cellulose. cDNA was
synthesized with 5.0Wg of mRNA by random hexam-
er priming using 1st strand cDNA synthesis kit
(CLONTECH).
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2.2. PCR with redundant primers and cloning of
TADG-12 cDNA
Redundant primers, forward 5P-TGGGTIGTIA-
CIGCIGCICA(CT)TG-3P and reverse 5P-A(AG)IA-
(AG)IGCIATITCITTICC-3P, for the consensus se-
quences of amino acids surrounding the catalytic tri-
ad for serine proteases were used to compare the
PCR products from normal and carcinoma cDNAs.
The appropriate bands were ligated into Promega T-
vector plasmid and the ligation product was used to
transform JM109 cells (Promega) grown on selection
media. After selection of individual colonies, they
were cultured and plasmid DNA was isolated by
means of the Wizard miniprep DNA puri¢cation sys-
tem (Promega). Nucleotide sequencing was per-
formed using PRISM Ready Reaction Dye Deoxy
terminator cycle sequencing kit (Applied Biosys-
tems). Applied Biosystems Model 373A DNA se-
quencing system was used for direct cDNA sequence
determination.
The original TADG-12 subclone was randomly la-
beled and used as a probe to screen an ovarian tu-
mor cDNA library by standard hybridization tech-
niques [11,16]. The library was constructed in VZAP
using mRNA isolated from the tumor cells of a stage
III/grade III ovarian adenocarcinoma patient. Three
overlapping clones were obtained which spanned
2315 nucleotides. The ¢nal 99 nucleotides encoding
the most 3P sequence including the poly(A) tail was
identi¢ed by homology with clones available in the
GenBank EST database.
2.3. Quantitative PCR
The mRNA overexpression of TADG-12 was de-
termined using a quantitative PCR. Quantitative
PCR was performed according to the procedure as
previously reported [17] Oligonucleotide primers
were used for: TADG-12, forward 5P-GAAA-
CATGTCCTTGCTCTCG-3P and reverse 5P-ACT-
AACTTCCACAGCCTCCT-3P ; the variant TADG-
12, forward 5P-TCCAGGTGGGTCTAGTTTCC-3P,
reverse 5P-CTCTTTGGCTTGTACTTGCT-3P ; L-tu-
bulin, forward 5P-CGCATCAACGTGTACTACAA-
3P and reverse 5P-TACGAGCTGGTGGACTGAG-
A-3P. L-Tubulin was utilized as an internal control.
The PCR reaction mixture consists of cDNA derived
from 50 ng of mRNA, 5 pmol of sense and antisense
primers for both the TADG-12 gene and the L-tubu-
lin gene, 200 Wmol of dNTPs, 5 WCi of [K-32P]dCTP
and 0.25 unit of Taq DNA polymerase with reaction
bu¡er (Promega) in a ¢nal volume of 25 Wl. The
target sequences were ampli¢ed in parallel with the
L-tubulin gene. Thirty cycles of PCR were carried
out in a Thermal Cycler (Perkin-Elmer Cetus).
Each cycle of PCR included 30 s of denaturation at
94‡C, 30 s of annealing at 60‡C and 30 s of extension
at 72‡C. The PCR products were separated on 2%
agarose gels and the radioactivity of each PCR
product was determined by using a Phospho Imager
(Molecular Dynamics). In the present study, we used
the expression ratio (TADG-12/L-tubulin) as mea-
sured by phosphoimager to evaluate gene expression
and de¢ned the value at mean+2S.D. of normal ova-
ry as the cuto¡ value to determine overexpression.
The Student’s t-test was used for comparison of the
mean values of normal ovary and tumors.
2.4. Antibody production
Polyclonal rabbit antibodies were generated by im-
munization of white New Zealand rabbits with a
poly-lysine linked multiple Antigen peptide derived
from the TADG-12 carboxy-terminal protein se-
quence NH2-WIHEQMERDLKT-COOH. This pep-
tide is present in full-length TADG-12, but not
TADG-12V. Rabbits were immunized with approx-
imately 100 Wg of peptide emulsi¢ed in Ribi adju-
vant. Subsequent boost immunizations were carried
out at 3 and 6 weeks, and rabbit serum was isolated
10 days after the boost inoculations. Sera were tested
by dot-blot analysis to determine a⁄nity for the
TADG-12 speci¢c peptide. Rabbit pre-immune se-
rum was used as a negative control.
2.5. Northern blot analysis
Ten Wg of mRNA was loaded onto a 1% form-
aldehyde^agarose gel, electrophoresed and blotted
on a Hybond-N+nylon membrane (Amersham).
32P-Labeled cDNA probes were made by Prime-a-
Gene Labeling System (Promega). The PCR prod-
ucts ampli¢ed by the same primers as above were
used for probes. The blots were prehybridized for
30 min and hybridized for 60 min at 68‡C with
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32P-labeled cDNA probe in ExpressHyb hybridiza-
tion solution (Clontech). Control hybridization to
determine relative gel loading was performed with
the L-tubulin probe.
Normal human tissues: spleen, thymus, prostate,
testis, ovary, small intestine, colon and peripheral
blood leukocyte; and normal human fetal tissues:
brain, lung, liver and kidney (Human Multiple Tis-
sue Northern Blot; Clontech) were also examined by
the same hybridization procedure.
2.6. Immunohistochemistry
Immunohistochemical staining was performed us-
ing a Vectastain Elite ABC kit (Vector). Formalin-
¢xed and para⁄n-embedded specimens were rou-
tinely depara⁄nized and processed using microwave
Fig. 1. (A) The expected PCR product of approximately 180 bp and the unexpected PCR product of approximately 300 bp using the
redundant serine protease primers were not ampli¢ed from normal ovary cDNA (lane 1) but were found in abundance from ovarian
tumor cDNA (lane 2). (B) TADG-12 was subcloned from the 180 bp band while the larger 300 bp band was designated TADG-12V.
The sequences were found to overlap for 180 bp with the 300 bp TADG-12V having an additional insert of 133 bases. This insertion
(vertical arrow) leads to a frame shift, which causes the TADG-12V transcript to potentially produce a truncated form of TADG-12
with a variant amino acid sequence. The primer sequences for the PCR reactions are indicated by horizontal arrows.
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heat treatment in 0.01 M sodium citrate bu¡er (pH
6.0). The specimens were incubated with normal goat
serum in a moist chamber for 30 min. TADG-12
peptide antibody was allowed to incubate with the
specimens in a moisture chamber for 1 h. Excess
antibody was washed away with phosphate-bu¡ered
saline. After incubation with biotinylated anti-rabbit
IgG for 30 min, the sections were then incubated
with ABC reagent (Vector) for 30 min. The ¢nal
products were visualized using the AEC substrate
system (Dako) and sections were counterstained
with hematoxylin before mounting. Negative con-
trols were performed by using normal serum instead
of the primary antibody.
3. Results
To identify serine proteases that are expressed in
ovarian tumors, we used redundant PCR primers
designed to the conserved regions of the catalytic
triad of these enzymes. In this study, a sense primer
designed to the region surrounding the conserved
histidine and an anti-sense primer designed to the
region surrounding the conserved aspartate were
used in PCR reactions with either normal ovary or
ovarian tumor cDNA as template. In the reaction
with ovarian tumor cDNA, we observed a strong
product band of the expected size of approximately
180 bp. In addition, we observed an unexpected PCR
product of approximately 300 bp which showed
strong expression in some ovarian tumor cDNAs
(Fig. 1A). Both of these PCR products were sub-
cloned and sequenced. The sequence of the subclones
from the 180 bp band was found to be homologous
to the sequence identi¢ed in the larger, unexpected
band except that the larger band had an additional
insert of 133 nucleotides (Fig. 1B). The smaller prod-
uct of the appropriate size encoded for a protein se-
quence homologous to other known proteases while
the sequence with the insertion encoded for a frame
shift from the serine protease catalytic domain and a
subsequent premature translational stop codon. We
also subcloned and sequenced TADG-12 variants
from four individual tumors and found the sequence
and insert to be identical. The genomic sequences for
these cDNA derived clones were ampli¢ed by PCR,
examined and found to contain potential AG/GT
splice sites that would allow for the variant transcript
production (data not shown).
To examine transcript size and tissue distribution,
the catalytic domain subclone was randomly labeled
and used to probe Northern blots representing nor-
mal ovarian tissue, ovarian tumors and the cancer
cell lines SW626, CAOV3, HeLa, MD-MBA-435S
and MD-MBA-231 (Fig. 2). Three transcripts of
2.4, 1.6 and 0.7 kb were observed. In blots of normal
and ovary tumor the smallest transcript size 0.7 kb
showed low expression in normal ovary while all
transcripts (2.4, 1.6 and 0.7 kb) were abundantly
present in serous carcinoma. In addition, Northern
blots representing the normal human tissues spleen,
thymus, prostate, testis, ovary, small intestine, colon
and peripheral blood leukocyte, and normal human
fetal tissues of brain, lung, liver and kidney were
examined. The same three transcripts were found to
be expressed weakly in all of these tissues (data not
shown). A human L-tubulin speci¢c probe was uti-
lized as a control for relative sample loading. In ad-
dition, we probed an RNA dot blot representing 50
human tissues and determined that this clone is
weakly expressed in all tissues represented (Fig. 3).
Fig. 2. Northern blot analysis for TADG-12 revealed three
transcripts of 2.4, 1.6 and 0.7 kb. These transcripts were found
at signi¢cant levels in ovarian tumors and cancer cell lines, but
the transcripts were found only at low levels in normal ovary.
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It was found most prominently in heart, with inter-
mediate levels in putamen, amygdala, kidney, liver,
small intestine, skeletal muscle, and adrenal gland.
With the knowledge that the largest transcript was
2.4 kb, we screened an ovarian tumor cDNA library
constructed in VZAP by standard hybridization tech-
niques using the catalytic domain subclone as a
probe. Two clones that overlapped with our probe
were identi¢ed and sequenced and found to represent
2315 nucleotides. The 99 nucleotides at the 3P end of
the transcript including the polyadenylation signal
and the poly(A) tail were identi¢ed by homology
with clones available in GenBank’s EST database.
This brought the total size of our transcript to
2414 bases (Fig. 4). Subsequent screening of Gen-
Bank’s Genomic database revealed that TADG-12
Fig. 3. An RNA dot blot (Clontech) was probed for TADG-12. The transcript was detectable (at background levels) in all 50 of the
human tissues represented with the greatest abundance of transcript in the heart. Putamen, amygdala, kidney, liver, small intestine,
skeletal muscle, and adrenal gland were also found to have intermediate levels of TADG-12 transcript.
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Fig. 4. The entire cDNA for TADG-12 is shown with its predicted open reading frame of 454 amino acids. Within the nucleotide se-
quence, the Kozak’s consensus sequence for the initiation of translation and the polyadenylation signal are underlined. In the protein
sequence, a potential transmembrane domain is boxed. The LDLR-A domain is underlined with a solid line. The SRCR domain is
underlined with a broken line. The residues of the catalytic triad of the serine protease domain are circled, and the beginning of the
catalytic domain is marked with an arrow designated as a potential proteolytic cleavage site. The asterisk represents the stop codon
that terminates translation.
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is homologous to a cosmid from chromosome 17.
This cosmid has the accession number AC015555.
The identi¢ed cDNA includes an open reading
frame that would produce a predicted protein of
454 amino acids, named Tumor Associated Di¡eren-
tially-expressed Gene-12 (TADG-12). The sequence
has been submitted to the GenBank database and
granted the accession number AF201380. Using ho-
mology alignment programs, this protein contains
several domains including an amino-terminal cyto-
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plasmic domain, a potential Type II transmembrane
domain followed by a low-density lipoprotein recep-
tor-like class A domain (LDLR-A), a scavenger re-
ceptor cysteine-rich domain (SRCR), and an extra-
cellular serine protease domain.
As predicted by the TMPred program, TADG-12
contains a highly hydrophobic stretch of amino acids
that could serve as a potential transmembrane do-
main, which would retain the amino terminus of
the protein within the cytoplasm and expose the li-
gand-binding domains and protease domain to the
extracellular space. This general structure is consis-
tent with other known transmembrane proteases in-
cluding hepsin [18], and TMPRSS2 [19], and TADG-
12 is particularly similar in structure to the
TMPRSS2 protease.
The LDLR-A domain of TADG-12, is represented
by the sequence from amino acid 74 to 108. The
LDLR-A domain was originally identi¢ed within
the LDL receptor [20] as a series of repeated sequen-
ces of approximately 40 amino acids, which con-
tained six invariant cysteine residues and highly con-
served aspartate and glutamate residues. Since that
initial identi¢cation, a host of other genes have been
identi¢ed which contain motifs homologous to this
domain [21]. Several proteases have been identi¢ed
which contain LDLR-A motifs including matriptase,
TMPRSS2 and several complement components. A
comparison of TADG-12 with other known LDLR-
A domains is shown in Fig. 5A. The similarity of
these sequences range from 44% to 54% of similar
or identical amino acids.
In addition to the LDLR-A domain, TADG-12
contains another extracellular ligand-binding domain
with homology to the group A SRCR family. This
family of protein domains typically is de¢ned by the
conservation of six cysteine resides within a sequence
of approximately 100 amino acids [24]. The SRCR
domain of TADG-12 is encoded by amino acids 109^
206, and this domain was aligned with other SRCR
domains and found to have between 36% and 43%
similarity (Fig. 5B). However, TADG-12 only has
Fig. 6. Semi-quantitative PCR was performed for TADG-12 (upper) and TADG-12V (lower). The ampli¢cation of TADG-12 or
TADG-12V was performed in parallel with PCR ampli¢cation of L-tubulin product as an internal control. The TADG-12 transcript
was found to be overexpressed in 41 of 55 carcinomas. The TADG-12V transcript was found to be overexpressed in eight of 22 carci-
nomas examined. Note that the samples in the upper panel are not necessarily the same as the samples in the lower panel.
Fig. 5. (A) The 35-amino-acid LDLR-A domain of TADG-12 is shown aligned with other LDLR-A motifs from the serine protease
TMPRSS2 (U75329), the complement subunit C8 (P07358), two LDLR-A domains of the glycoprotein GP300 (P98164), and the ser-
ine protease matriptase (AF118224). TADG-12 has its highest similarity with the other serine proteases for which it is 54% similar to
TMPRSS2 and 53% similar to matriptase. The highly conserved cysteine residues are shown in bold type. (B) The SRCR domain of
TADG-12 is shown aligned with other domain family members including the human macrophage scavenger receptor (P21757), human
enterokinase (P98073), bovine enterokinase (P21758), and the serine protease TMPRSS2. Again, TADG-12 shows its highest similarity
within this region to the protease TMPRSS2 at 43%. (C) The protease domain of TADG-12 is shown in alignment with other human
serine proteases including protease M (U62801), trypsinogen I (P07477), plasma kallikrein (P03952), hepsin (P05981), and TMPRSS2.
Cons, the consensus sequence for each alignment.
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four of the six conserved cysteine residues. This is
similar to the SRCR domain found in the protease
TMPRSS2.
The TADG-12 protein also includes a serine pro-
tease domain of the trypsin family of proteases. An
alignment of the catalytic domain of TADG-12 with
other known proteases is shown in Fig. 5C. The sim-
ilarity among these sequences ranges from 48% to
55%, and TADG-12 is most similar to the serine
protease TMPRSS2 which also contains a transmem-
brane domain, LDLR-A domain and an SRCR do-
main. There is a conserved amino acid motif
(RIVGG) downstream from the SRCR domain
that is a potential cleavage/activation site common
to many serine proteases of this family [26]. This
suggests that TADG-12 is tra⁄cked to the cell sur-
face where the ligand-binding domains are capable of
interacting with extracellular molecules and the pro-
tease domain is potentially activated. TADG-12 also
contains conserved cysteine residues (amino acids
208 and 243) which in other proteases form a disul-
¢de bond capable of linking the activated protease to
the other extracellular domains. Finally, TADG-12
contains a trypsin-like serine protease domain. Based
on its homology with TMPRSS2 and conservation of
Asp395 within the catalytic site, we suspect that
TADG-12 might be capable of cleaving peptides
after lysine or arginine residues [19].
The original TADG-12 subclone was identi¢ed as
highly expressed in our initial redundant-primer PCR
experiment. The TADG-12 variant form (TADG-
12V) with the insertion of 133 bp was also easily
detected in the initial experiment. To identify the
frequency of this expression and whether or not the
expression level between normal ovary and ovarian
tumors was di¡erent, we employed a previously au-
thenticated semi-quantitative PCR technique [17]. In
this PCR analysis, we co-ampli¢ed a product for
L-tubulin with either a product speci¢c to TADG-
12 or TADG-12V in the presence of a radiolabeled
nucleotide. The products were separated by agarose
gel electrophoresis and a phosphoimager was used to
quantitate the relative abundance of each PCR prod-
uct. Examples of these PCR ampli¢cation products
are shown for both TADG-12 and TADG-12V in
Fig. 6. Normal expression was de¢ned as the mean
Fig. 7. Immunohistochemical staining of normal ovary and ovarian tumors were performed using a polyclonal rabbit antibody devel-
oped to a TADG-12 speci¢c peptide. (A) No signi¢cant staining was detected in normal ovary. Strong positive staining was observed
in 22 of 29 carcinomas examined. (B,C) A serous and mucinous carcinoma, respectively. Both show di¡use staining throughout the
cytoplasm of tumor cells while stromal cells remain relatively unstained.
Table 2
Frequency of overexpression of TADG-12V in ovarian carcino-
ma
Histology type TADG-12V (%)
Normal 0/10 (0%)
LMP^serous 0/5 (0%)
LMP^mucinous 0/3 (0%)
Serous carcinoma 4/14 (29%)
Mucinous carcinoma 3/5 (60%)
Endometrioid carcinoma 1/3 (33%)
Clear cell carcinoma Not determined
Table 1
Frequency of overexpression of TADG-12 in ovarian carcinoma
Histology type TADG-12 (%)
Normal 0/16 (0%)
LMP^serous 3/6 (50%)
LMP^mucinous 0/4 (0%)
Serous carcinoma 23/29 (79%)
Mucinous carcinoma 7/12 (58%)
Endometrioid carcinoma 8/8 (100%)
Clear cell carcinoma 3/6 (50%)
Benign tumors 3/4 (75%)
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ratio of TADG-12 (or TADG-12V) to L-tubu-
lin þ 2S.D. as examined in normal ovarian samples.
For tumor samples, overexpression was de¢ned as
s 2S.D. from the normal TADG-12/L-tubulin or
TADG-12V/L-tubulin ratio. The results are summa-
rized in Tables 1 and 2. TADG-12 was found to be
overexpressed in 41 of 55 carcinomas examined while
the variant form was present at aberrantly high levels
in eight of 22 carcinomas. As determined by the Stu-
dent’s t-test, these di¡erences were statistically signif-
icant (P6 0.05).
In order to examine the TADG-12 protein, we
developed polyclonal rabbit anti-sera to a peptide
located in the carboxy-terminal amino acid sequence.
These antibodies were used to examine the expres-
sion level of the TADG-12 protein and its localiza-
tion within normal ovary and ovarian tumor cells by
immunolocalization. No staining was observed in
normal ovarian tissues (Fig. 7A) while signi¢cant
staining was observed in 22 of 29 tumors studied.
Representative tumor samples are shown in Fig. 7B
and C. It should be noted that TADG-12 is found in
a di¡use pattern throughout the cytoplasm indicative
of a protein in a tra⁄cking pathway. It should also
be noted that the antibody developed and used for
immunohistochemical analysis would not detect the
TADG-12V truncated protein.
4. Discussion
In this study, we have identi¢ed a novel serine
protease by means of a PCR-based strategy. By
Northern blot, the largest transcript for this gene is
approximately 2.4 kb, and it is found to be expressed
at high levels in ovarian tumors while found at min-
imal levels in all other tissues examined. We have
cloned the full-length cDNA encoding a novel mul-
ti-domain, cell-surface serine protease, named
TADG-12. The 454 amino acid protein contains a
cytoplasmic domain, a type II transmembrane do-
main, an LDLR-A domain, an SRCR domain and
a serine protease domain.
We have also shown using a semi-quantitative
PCR analysis and immunohistochemistry that
TADG-12 is overexpressed in a majority of tumors
studied. The most prevalent subtype of ovarian epi-
thelial cancer is serous carcinoma, TADG-12 over-
expression was found in 79% of these sample types.
The next most common subtype is mucinous carci-
noma which displays 58% overexpression. Mucinous
tumors are generally deemed to be less aggressive
than the other histological forms. Endometrioid
and clear cell carcinomas are very aggressive tumors
and these histologies overexpressed TADG-12 in
100% and 50% of cases, respectively. Due to incom-
plete pathology information, it is impossible to tell at
this time if TADG-12 overexpression correlates pos-
itively with metastasis. In some individual cases
where lymph nodes were examined for metastases,
TADG-12 was found to be overexpressed while in
other cases TADG-12 was not found in association
with metastasis. Therefore, the precise role of
TADG-12 with regard to malignancy and aggressive-
ness remains unclear. Recently, the serine protease
trypsin has been associated with ovarian cancer and
shown to correlate positively with invasiveness and
metastatic potential [27]. Association of trypsin with
LMP disease was a negative indicator of prognosis.
Although our pathology data is incomplete we ex-
pect TADG-12 to increase aggressiveness of disease
by increasing the proteolytic activity associated with
tumors in a manner similar to trypsin.
Interestingly, TADG-12 also has a variant splicing
form that is present in 35% of the tumors we studied.
While the normal TADG-12 protein would be ex-
pected to be found at the cell surface where it may
serve proteolytic functions similar to other surface
serine proteases, the TADG-12V mRNA would
lead to a truncated protein that may provide a novel
surface epitope unique to tumor cells.
This protein contains extracellular domains which
might confer unusual properties to this multidomain
molecule. Although the precise role of LDLR-A
function with regard to proteases remains unclear,
this domain certainly has the capacity to bind calci-
um and other positively charged ligands [22,23]. This
may play an important role in the regulation of the
protease or subsequent internalization of the mole-
cule. The SRCR domain was originally identi¢ed
within the macrophage scavenger receptor and func-
tionally described to bind lipoproteins. Not only are
SRCR domains capable of binding lipoproteins, but
they may also bind to molecules as diverse as poly-
nucleotides [24]. More recent studies have identi¢ed
members of this domain family in proteins with func-
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tions that vary from proteases to cell adhesion mol-
ecules involved in maturation of the immune system
[25]. In addition, TADG-12, like TMPRSS2 has only
four of six cysteine residues conserved within its
SRCR domain. This di¡erence may allow for di¡er-
ent structural features of these domains that confer
unusual ligand-binding properties. At this time, only
the function of the CD6 encoded SRCR is well docu-
mented. In the case of CD6, the SRCR domain binds
to the cell adhesion molecule ALCAM [24]. This
mediation of cell adhesion is a useful starting point
for future research on newly identi¢ed SRCR do-
mains; however, the possibility of multiple functions
for this domain cannot be overlooked. SRCR do-
mains are certainly capable of cell adhesion type in-
teractions, but their capacity to bind other types of
ligands should be considered.
At this time, the precise role of TADG-12 remains
unclear. Substrates have not been identi¢ed for the
protease domain, nor have ligands been identi¢ed for
the extracellular LDLR-A and SRCR domains. Both
TADG-12 and TMPRSS2 clearly are closely related
family members of the transmembrane serine pro-
tease group. Because both enzymes present a similar
array of extracellular ligand-binding domains, it is
tempting to propose that the protease functional ac-
tivity of these enzymes is closely linked to substrates
which might associate with the extracellular ligand-
binding domain. In both cases, activation of the pro-
tease is mediated most likely by the cleavage of the
conserved RIVGG sequences upstream of the cata-
lytic domain and their family association with the
conserved ASP395 group suggests substrate cleavage
at arginine or lysine groups. In Fig. 8, we present a
Fig. 8. In this model, we describe the progression of TADG-12 within a cellular context. In normal circumstances, the TADG-12 tran-
script is appropriately spliced and the resulting protein is capable of being expressed at the cell surface where the protease may be
cleaved to an active form. The role of the remaining ligand-binding domains has not yet been determined, but one can envision their
potential to bind other molecules for activation, internalization or both. The TADG-12V transcript, which occurs in some tumors,
may be the result of mutation and/or poor mRNA processing may be capable of producing a truncated form of TADG-12 that does
not have a functional protease domain. In addition, this truncated product may present a novel epitope at the surface of tumor cells.
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working model of our vision of TADG-12 with the
information in our possession. Two transcripts are
produced which lead to the production of either
TADG-12 or the truncated TADG-12V proteins. Ei-
ther of these proteins are potentially targeted to the
cell surface. TADG-12 is capable of becoming an
activated serine protease while TADG-12V is a trun-
cated protein product that if at the cell surface may
represent a tumor-speci¢c epitope. TADG-12 con-
tains an RIVGG motif that is common to many
serine proteases. This amino acid sequence is recog-
nized as a proteolytic activation sequence that must
be cleaved to obtain a functional protease [26]. This
feature implies that TADG-12 is produced as an in-
active precursor molecule, and at this time, it re-
mains unclear whether active TADG-12 is present
in tumors.
The problem with treatment of ovarian cancer to-
day remains the inability to diagnose the disease at
an early stage. Identifying genes that are expressed
early in the disease process such as proteases that are
essential for tumor cell growth [28] is an important
step toward improving treatment. With this knowl-
edge, it may be possible to design assays to detect the
highly expressed genes such as the TADG-12 pro-
tease described here or previously described pro-
teases to diagnose these cancers at an earlier stage.
Panels of markers may also provide prognostic in-
formation and could lead to therapeutic strategies
for individual patients. Alternatively, inhibition of
enzymes such as proteases may be an e¡ective means
for slowing progression of ovarian cancer and im-
proving the quality of patient life. Other features of
TADG-12 and TADG-12V must be considered im-
portant to future research too. The extracellular li-
gand-binding domains are natural targets for drug
delivery systems. The aberrant peptide associated
with the TADG-12V protein may provide an excel-
lent target drug delivery or for immune stimulation.
The value of these approaches will become more as-
sessable as we continue to investigate their usefulness
in patient care.
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